Shingles Vaccination of U.S. Adults Aged 50–59 Years and ≥60 Years Before Recommendations for Use of Recombinant Zoster Vaccine
| Autor: | Mei-Chuan Hung, Walter W. Williams, Kathleen L. Dooling, Anup Srivastav, Peng-jun Lu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Herpes Zoster Vaccine Epidemiology Herpes Zoster 01 natural sciences Article 03 medical and health sciences Mississippi 0302 clinical medicine Vaccination status Health care Humans Medicine 030212 general & internal medicine 0101 mathematics Aged National health Behavioral Risk Factor Surveillance System business.industry Vaccination 010102 general mathematics Public Health Environmental and Occupational Health Middle Aged Pennsylvania medicine.disease South Dakota Female Zoster vaccine business Shingles medicine.drug |
| Zdroj: | Am J Prev Med |
| ISSN: | 0749-3797 |
| Popis: | Introduction In 2006, zoster vaccine live was recommended for adults aged ≥60 years. In 2011, zoster vaccine live was approved for use but not recommended for adults aged 50–59 years. This study assessed zoster vaccine live coverage among adults aged 50–59 years and ≥60 years. Methods Data from the 2013–2017 National Health Interview Surveys were analyzed in 2019 to estimate national zoster vaccine live coverage among adults aged ≥50 years. State-specific zoster vaccine live coverage among adults aged ≥50 years was assessed using 2017 Behavioral Risk Factor Surveillance System data. Results Among adults aged 50–59 years, zoster vaccine live coverage was 5.7% in 2017, ranging from 4% to 6% during 2013–2017 (test for trend, p>0.05). Zoster vaccine live coverage among adults aged 50–59 years ranged from 5.8% in Pennsylvania to 14.7% in South Dakota. By 2017, zoster vaccine live was received by 34.9% of adults aged ≥60 years, a significant increase from 24.2% in 2013. Zoster vaccine live coverage among adults aged ≥60 years in 2017 ranged from 26.0% in Mississippi to 51.8% in Vermont. In 2017, major characteristics significantly associated with increased likelihood of zoster vaccine live vaccination among adults aged 50–59 years and ≥60 years were older age, having 4 to 9 physician contacts in the past 12 months, and having a usual place for health care. Conclusions This study provides an assessment of zoster vaccine live coverage among adults aged ≥50 years before the newly recommended recombinant zoster vaccine came into widespread use. Providers should routinely assess adults’ vaccination status and strongly recommend or offer needed vaccines to their patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect